Theravance Biopharma (Theravance Biopharma) Debt-to-Equity : 0.23 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Debt-to-Equity?

Theravance Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.92 Mil. Theravance Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $45.24 Mil. Theravance Biopharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $213.00 Mil. Theravance Biopharma's debt to equity for the quarter that ended in Dec. 2023 was 0.23.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Theravance Biopharma's Debt-to-Equity or its related term are showing as below:

TBPH' s Debt-to-Equity Range Over the Past 10 Years
Min: -8.81 Med: -0.93 Max: 1.94
Current: 0.23

During the past 12 years, the highest Debt-to-Equity Ratio of Theravance Biopharma was 1.94. The lowest was -8.81. And the median was -0.93.

TBPH's Debt-to-Equity is ranked worse than
59.79% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs TBPH: 0.23

Theravance Biopharma Debt-to-Equity Historical Data

The historical data trend for Theravance Biopharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Debt-to-Equity Chart

Theravance Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-2.28

-2.23

-1.98

0.12

0.23

Theravance Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.12	0.14	0.18	0.21	0.23

Competitive Comparison of Theravance Biopharma's Debt-to-Equity

For the Biotechnology subindustry, Theravance Biopharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theravance Biopharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Debt-to-Equity falls into.

Theravance Biopharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Theravance Biopharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.923	+	45.236)	/	212.995
	=	0.23

Theravance Biopharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.923	+	45.236)	/	212.995
	=	0.23

Theravance Biopharma (NAS:TBPH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Theravance Biopharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Theravance Biopharma (Theravance Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (NAS:TBPH) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

0TB:Germany

Address

Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104

Website

https://www.theravance.com

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Executives

Rhonda Farnum	officer: SVP, Comm & Medical Affairs	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Richard A Graham	officer: SVP, Development	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kelly James Connor	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Brett A. Grimaud	officer: SVP, Gen Counsel and Secretary	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Aziz Sawaf	officer: SVP & Chief Financial Officer	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Rick E Winningham	director, officer: Chief Executive Officer	901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Andrew A. Hindman	officer: SVP, Chief Financial Officer	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Eli Samaha	10 percent owner	ONE WORLD TRADE CENTER, FLOOR 65, NEW YORK NY 10007
Wam Gp Llc	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Andrew M Weiss	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Weiss Asset Management Lp	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Philip D Worboys	officer: SVP, Translational Science	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Brett K Haumann	officer: VP-Clinical Develop.	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Deepika Pakianathan	director	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402